category details

0209002N) PROGENI: Parkinson's Research: The Organized Genetics Initiative
        Current Status:   Active & Enrolling   |  Contact Us
        Principal Investigator:  Paul Tuite MD
        For more information call toll-free at 1(888)830-6299. For those residing outside of the United States call 1(317)274-5734. Information about the study can also be obtained through our website at http://www.medgen.iupui.edu/research/parkinson/. To speak to someone at the University of Minnesota call (612)625-7973.

0304002) CNS penetration and safety of an investigational drug in patients with ALS
        Current Status:   Active & Enrolling   |  Contact Us
         Gareth J. Parry MD

0311001) Randomized evaluation of recurrent stroke
        Current Status:   Active & Enrolling   |  Contact Us
         Gareth J. Parry MD

0401010) The effect of aging on glueuronidation of antiepileptic drugs: valproic acidEffect of age on VPA
        Current Status:   Active & Enrolling   |  Contact Us
        Principal Investigator:  Rory Remmel PhD

0411014) Preventing neutralizing antibodies in multiple sclerosis patients being treated with subcutaneous investigational drug
        Current Status:   Active & Enrolling   |  Contact Us
         Gareth J. Parry MD

0411015) A multi-centered, randomized, double-blind, placebo controlled study assessing the add-on effect of oral steroids in relapsing remitting multiple sclerosis subjects treated with an investigational drug
        Current Status:   Active & Enrolling   |  Contact Us
         Gareth J. Parry MD

0703001N) Movement Disorders Registry
        Current Status:   Active & Enrolling   |  Contact Us
         Paul Tuite MD
        The Movement Disorders Clinical Registry is a voluntary database. Subjects are selected from this registry to be participants in movement disorder studies. Healthy individuals are encouraged to contact us as well as individuals with a Parkinson's disease diagnosis. Studies are conducted on a continuous basis.

0110005N) A Bi-national, Multicenter, Double-Blind, Randomized Study to Evalyate the Safety and Tolerability of an investigational drug in Advanced Parkinson's Disease Patients with Motor Fluctuations Treated with Chronic Levodopa/Carbidopa Therapy (PRESTO)
        Current Status:   Active and Not Enrolling
        Principal Investigator:  David Rottenberg M.D.
        For more information go to http://www.neurovia.umn.edu/parkinsons/Parkinsons.html

0204001) A randomized, double-blind, placebo-controlled, dose-finding study to assess the efficacy and safety of an investigational drug in patients with early Parkinson's disease
        Current Status:   Active and Not Enrolling
        Principal Investigator:  Paul Tuite MD

0208002N) A Multicenter, Multinational, Phase III, Randomized, Double Blind, Parallel Group, Placebo-Controlled Trial of the Efficacy and Safety of an investigational drug Patch (2 Target Doses) in Subjects With Advanced Stage Idiopathic Parkinson's Disease
        Current Status:   Active and Not Enrolling
        Principal Investigator:  David Rottenberg M.D.
        For more information visit www.neurovia.umn.edu. Located at the VA Medical Center in Minneapolis

0402001N)
        Current Status:   Active and Not Enrolling
        Principal Investigator:  Paul Tuite MD

0404020) Phase IV, multicenter, open-label, randomized study of an investigational drug 44 mcg administered three times per week by subcutaneous injection compared with an investigational drug 20 mg administered daily by subcutaneous injection in the treatment of relapsing remitting multiple sclerosis.
        Current Status:   Active and Not Enrolling
         Gareth J. Parry MD